Phase I design for completely or partially ordered treatment schedules. - Wikidata - awgldk - TriplyDB

Phase I design for completely or partially ordered treatment schedules.

Phase I design for completely or partially ordered treatment schedules.

http://www.wikidata.org/entity/Q30407970

about

Designs for phase I trials in ordered groups.Performance of toxicity probability interval based designs in contrast to the continual reassessment method.Phase I/II adaptive design for drug combination oncology trials Design considerations for early-phase clinical trials of immune-oncology agents

P2860

Q30275947-F28688B4-0E44-4582-8E02-178EE23BD589 Q30276332-46A4D751-A4CF-4190-8DA5-2C4F9916E4A5 Q30409168-2821D9E1-85CD-4AF9-A59D-C796FA07823D Q56334001-1B100EB9-82C3-4C86-84CB-9403F7335542

P2860

Phase I design for completely or partially ordered treatment schedules.

http://www.wikidata.org/entity/Q30407970

description

2013 nî lūn-bûn

@nan

2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Phase I design for completely or partially ordered treatment schedules.

@ast

Phase I design for completely or partially ordered treatment schedules.

@en

type

label

Phase I design for completely or partially ordered treatment schedules.

@ast

Phase I design for completely or partially ordered treatment schedules.

@en

prefLabel

Phase I design for completely or partially ordered treatment schedules.

@ast

Phase I design for completely or partially ordered treatment schedules.

@en

P1433

Q30407970-FDC3383F-7859-4394-8C40-3FB7FCD70083

P1476

Q30407970-852DF7ED-D96B-49CB-A289-FCC0F5636602

P2093

Q30407970-0B5D07EE-DA59-4792-8F76-019AE826E266

Q30407970-64CA7986-C4DB-4C94-B18E-816459D9B72E

Q30407970-9168470F-26EF-4340-81A4-76863EF18600

P2860

Q30407970-0D245341-E445-4991-B37A-B368823064ED

Q30407970-2CD05C36-7F65-49E7-9502-595E676305EA

Q30407970-416EED75-5F8B-4A26-9B5D-8A7E56C21818

Q30407970-5350C472-B23B-4EF3-81EC-4BCA3568175F

Q30407970-74F7F9FA-5CC2-445B-A4C2-5EFEBB1FA449

Q30407970-7B43D3DD-6321-40D6-A6D6-06095933CFD7

Q30407970-7D99DEA6-13A0-4399-826A-DCA91DCE2481

Q30407970-7E86DC20-2301-4BA0-A683-F8632C2DA00B

Q30407970-80FB8B0B-3683-42F7-B2A3-40A27269FBCD

Q30407970-DD79689C-1220-4A0C-9889-FA07026412D7

P304

Q30407970-A446014D-91B9-4A2C-93C6-7E9F7A88C297

P31

Q30407970-0F2085A6-2F32-476B-B955-084D08C77AC5

P356

Q30407970-18544FB1-0FBA-49FF-B1B9-A6A3804F88AD

P407

Q30407970-73144151-82DF-4A8F-9EB3-9C634509F792

P433

Q30407970-3550DBFC-C5C0-4AB2-8A9F-668D346C7FDE

P478

Q30407970-A682A55A-1071-4A7E-AE9B-B1CCAC7A241B

P577

Q30407970-C61A5D1D-D00B-4E5A-9110-7C034C2AB3D9

P698

Q30407970-F662FCEE-E084-44C9-8066-140183D5538F

P932

Q30407970-16B5886E-6822-4D28-B2BA-B97A39AE03A3

P356

P1433

Statistics in Medicine

P1476

Phase I design for completely or partially ordered treatment schedules.

@en

P2093

John O'Quigley

http://www.w3.org/2001/XMLSchema#string

Mark R Conaway

http://www.w3.org/2001/XMLSchema#string

Nolan A Wages

http://www.w3.org/2001/XMLSchema#string

P2860

Specifications of a continual reassessment method design for phase I trials of combined drugs.

Continual reassessment method for partial ordering.

Dose-finding design for multi-drug combinations.

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.

Model calibration in the continual reassessment method.

Dose--schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation.

A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies.

Non-parametric optimal design in dose finding studies.

Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

Determining a maximum-tolerated schedule of a cytotoxic agent.

P304

569-579

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/SIM.5998

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24114957

http://www.w3.org/2001/XMLSchema#string

P932

3947103

http://www.w3.org/2001/XMLSchema#string